Dynavax Technologies

Valuation Analysis

About the Company

Dynavax Technologies en bref

Dynavax Technologies (DVAX) is currently trading at 13,53 € with a market capitalization of 1,6 Md €. The 52-week range spans from 0,00 € to 13,73 €; the current price is 1.5% below the yearly high. Year-over-year revenue growth stands at +17.7%.

💰 Dividende

Dynavax Technologies currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

1 analystes évaluent Dynavax Technologies (DVAX) au consensus : Achat Fort. L'objectif de cours moyen est de 13,96 €, soit un potentiel de +3.23% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 13,96 € à 13,96 €.

Dynavax Technologies : la thèse d'investissement en détail

Dynavax Technologies (DVAX) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 17.7% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 69.3% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 61.6%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 13.19% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 60.37x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (13.19%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Dynavax Technologies?

Compare top-rated brokers — low fees, trusted providers, fully regulated.